Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

5.5K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
5.5K
The Ras Gene02:38

The Ras Gene

6.5K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
6.5K
Abnormal Proliferation02:23

Abnormal Proliferation

4.7K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.7K
Mouse Models of Cancer Study02:43

Mouse Models of Cancer Study

5.8K
Mice have long served as models for studying human biology and pathology because of their phylogenetic and physiological similarity with humans. They are also easy to maintain and breed in the laboratory, and hence, many inbred strains are now available for research. Studies on mice have contributed immeasurably to our understanding of cancer biology.
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
5.8K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

4.3K
Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
4.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Novel Polycaprolactone Composite Nanofiber Dressing Co-Loaded With Propolis and Silver Nanoparticles for Faster Wound Healing: In Vivo Evidence.

Journal of biomedical materials research. Part B, Applied biomaterials·2026
Same author

CD4 expression controls epidermal stem cell balance.

Scientific reports·2025
Same author

AXIN1 bi-allelic variants disrupting the C-terminal DIX domain cause craniometadiaphyseal osteosclerosis with hip dysplasia.

American journal of human genetics·2023
Same author

The hidden hedgehog of the pituitary: hedgehog signaling in development, adulthood and disease of the hypothalamic-pituitary axis.

Frontiers in endocrinology·2023
Same author

Tumor suppressive functions of WNT5A in rhabdomyosarcoma.

International journal of oncology·2022
Same author

Context-dependent modulation of aggressiveness of pediatric tumors by individual oncogenic RAS isoforms.

Oncogene·2021

Related Experiment Video

Updated: Oct 9, 2025

Initiation of Metastatic Breast Carcinoma by Targeting of the Ductal Epithelium with Adenovirus-Cre: A Novel Transgenic Mouse Model of Breast Cancer
07:13

Initiation of Metastatic Breast Carcinoma by Targeting of the Ductal Epithelium with Adenovirus-Cre: A Novel Transgenic Mouse Model of Breast Cancer

Published on: March 26, 2014

23.5K

Oncogenic NRAS Accelerates Rhabdomyosarcoma Formation When Occurring within a Specific Time Frame during Tumor

Nada Ragab1, Julia Bauer1, Dominik S Botermann1

  • 1Department of Human Genetics, University Medical Center Goettingen, 37073 Goettingen, Germany.

International Journal of Molecular Sciences
|December 24, 2021
PubMed
Summary
This summary is machine-generated.

Activating NRAS mutations in early embryonal rhabdomyosarcoma (ERMS) precursors accelerate tumor growth. This occurs within a specific developmental window, highlighting isoform-specific roles in tumor progression.

Keywords:
RAS mutationembryonal RMSpermissive window

More Related Videos

In Vitro Establishment of a Genetically Engineered Murine Head and Neck Cancer Cell Line using an Adeno-Associated Virus-Cas9 System
05:45

In Vitro Establishment of a Genetically Engineered Murine Head and Neck Cancer Cell Line using an Adeno-Associated Virus-Cas9 System

Published on: January 9, 2020

8.1K
A Genetically Engineered Mouse Model of Sporadic Colorectal Cancer
06:01

A Genetically Engineered Mouse Model of Sporadic Colorectal Cancer

Published on: July 6, 2017

9.7K

Related Experiment Videos

Last Updated: Oct 9, 2025

Initiation of Metastatic Breast Carcinoma by Targeting of the Ductal Epithelium with Adenovirus-Cre: A Novel Transgenic Mouse Model of Breast Cancer
07:13

Initiation of Metastatic Breast Carcinoma by Targeting of the Ductal Epithelium with Adenovirus-Cre: A Novel Transgenic Mouse Model of Breast Cancer

Published on: March 26, 2014

23.5K
In Vitro Establishment of a Genetically Engineered Murine Head and Neck Cancer Cell Line using an Adeno-Associated Virus-Cas9 System
05:45

In Vitro Establishment of a Genetically Engineered Murine Head and Neck Cancer Cell Line using an Adeno-Associated Virus-Cas9 System

Published on: January 9, 2020

8.1K
A Genetically Engineered Mouse Model of Sporadic Colorectal Cancer
06:01

A Genetically Engineered Mouse Model of Sporadic Colorectal Cancer

Published on: July 6, 2017

9.7K

Area of Science:

  • Oncology
  • Developmental Biology
  • Genetics

Background:

  • Embryonal rhabdomyosarcoma (ERMS) is a pediatric cancer.
  • RAS (Rat Sarcoma) oncogenes, including HRAS, KRAS, and NRAS, are frequently implicated in cancer development.
  • The timing of oncogenic mutations during tumor development can influence their impact.

Purpose of the Study:

  • To investigate the role of NRAS mutations in ERMS development at an earlier precursor stage (2 weeks of age).
  • To determine if NRAS mutations affect tumor initiation, growth acceleration, or differentiation in ERMS.
  • To compare the effects of NRAS mutations with HRAS and KRAS mutations at different developmental stages.

Main Methods:

  • Utilized the Ptch+/- mouse model for ERMS.
  • Induced oncogenic NRAS mutations at specific time points (2 weeks of age) during ERMS precursor development.
  • Monitored tumor incidence, tumor-free survival, and tumor differentiation.

Main Results:

  • Induction of oncogenic NRAS at 2 weeks of age significantly accelerated ERMS tumor growth.
  • This acceleration was evidenced by shortened ERMS-free survival and increased ERMS incidence.
  • Oncogenic NRAS at this early stage did not appear to alter tumor differentiation or be involved in tumor initiation.

Conclusions:

  • Oncogenic NRAS mutations can promote ERMS tumor growth when introduced into immature precursors within a critical time window.
  • The effects of NRAS mutations are dependent on the developmental stage of the target cells.
  • These findings underscore the differential roles of RAS isoforms and their timing of activation in cancer development.